

# Type I Interferon Susceptibility Distinguishes SARS-Co

Journal of Virology

94,

DOI: [10.1128/jvi.01410-20](https://doi.org/10.1128/jvi.01410-20)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Evasion of Type I Interferon by SARS-CoV-2. <i>Cell Reports</i> , 2020, 33, 108234.	6.4	742
2	SARS-CoV-2 Disrupts Splicing, Translation, and Protein Trafficking to Suppress Host Defenses. <i>Cell</i> , 2020, 183, 1325-1339.e21.	28.9	442
3	Exploring the role of triazole functionalized heteroatom co-doped carbon quantum dots against human coronaviruses. <i>Nano Today</i> , 2020, 35, 101001.	11.9	52
4	Immunology of COVID-19 and disease-modifying therapies: the good, the bad and the unknown. <i>European Journal of Neurology</i> , 2020, 28, 3503-3516.	3.3	20
5	Pathophysiology and Potential Therapeutic Candidates for COVID-19: A Poorly Understood Arena. <i>Frontiers in Pharmacology</i> , 2020, 11, 585888.	3.5	11
6	Lessons for COVID-19 Immunity from Other Coronavirus Infections. <i>Immunity</i> , 2020, 53, 248-263.	14.3	281
7	Contribution of monocytes and macrophages to the local tissue inflammation and cytokine storm in COVID-19: Lessons from SARS and MERS, and potential therapeutic interventions. <i>Life Sciences</i> , 2020, 257, 118102.	4.3	248
8	Emerging pharmacological therapies for ARDS: COVID-19 and beyond. <i>Intensive Care Medicine</i> , 2020, 46, 2265-2283.	8.2	52
9	Direct Exposure to SARS-CoV-2 and Cigarette Smoke Increases Infection Severity and Alters the Stem Cell-Derived Airway Repair Response. <i>Cell Stem Cell</i> , 2020, 27, 869-875.e4.	11.1	74
10	COVID-19: The Emerging Immunopathological Determinants for Recovery or Death. <i>Frontiers in Microbiology</i> , 2020, 11, 588409.	3.5	19
11	The immune system as a target for therapy of SARS-CoV-2: A systematic review of the current immunotherapies for COVID-19. <i>Life Sciences</i> , 2020, 258, 118185.	4.3	70
12	The potential similarities of COVID-19 and autoimmune disease pathogenesis and therapeutic options: new insights approach. <i>Clinical Rheumatology</i> , 2020, 39, 3223-3235.	2.2	29
13	COVID-19: Infection or Autoimmunity. <i>Frontiers in Immunology</i> , 2020, 11, 2055.	4.8	41
14	Antagonism of Type I Interferon by Severe Acute Respiratory Syndrome Coronavirus 2. <i>Journal of Interferon and Cytokine Research</i> , 2020, 40, 543-548.	1.2	31
15	In-line treatments and clinical initiatives to fight against COVID-19 outbreak. <i>Respiratory Medicine</i> , 2022, 191, 106192.	2.9	15
16	Potential role of interferons in treating COVID-19 patients. <i>International Immunopharmacology</i> , 2021, 90, 107171.	3.8	55
17	Proteomics in the COVID-19 Battlefield: First Semester Check-Up. <i>Proteomics</i> , 2021, 21, 2000198.	2.2	18
18	Randomized controlled open label trial on the use of favipiravir combined with inhaled interferon beta-1b in hospitalized patients with moderate to severe COVID-19 pneumonia. <i>International Journal of Infectious Diseases</i> , 2021, 102, 538-543.	3.3	72

#	ARTICLE	IF	CITATIONS
19	Azithromycin in viral infections. <i>Reviews in Medical Virology</i> , 2021, 31, e2163.	8.3	89
20	Single cell resolution of SARS-CoV-2 tropism, antiviral responses, and susceptibility to therapies in primary human airway epithelium. <i>PLoS Pathogens</i> , 2021, 17, e1009292.	4.7	76
21	Therapeutics and Vaccines: Strengthening Our Fight Against the Global Pandemic COVID-19. <i>Current Microbiology</i> , 2021, 78, 435-448.	2.2	9
22	The roles of signaling pathways in SARS-CoV-2 infection; lessons learned from SARS-CoV and MERS-CoV. <i>Archives of Virology</i> , 2021, 166, 675-696.	2.1	66
23	A single-cell mathematical model of SARS-CoV-2 induced pyroptosis and the effects of anti-inflammatory intervention. <i>AIMS Mathematics</i> , 2021, 6, 6050-6086.	1.6	2
24	Can SARS-CoV-2 Virus Use Multiple Receptors to Enter Host Cells?. <i>International Journal of Molecular Sciences</i> , 2021, 22, 992.	4.1	106
26	Severe Acute Respiratory Syndrome Coronavirus 2: Manifestations of Disease and Approaches to Treatment and Prevention in Humans. <i>Comparative Medicine</i> , 2021, 71, 342-358.	1.0	3
27	Innate immune evasion mediated by picornaviral 3C protease: Possible lessons for coronaviral 3C-like protease?. <i>Reviews in Medical Virology</i> , 2021, 31, 1-22.	8.3	18
28	Roles of Type I and III Interferons in COVID-19. <i>Yonsei Medical Journal</i> , 2021, 62, 381.	2.2	17
29	Molecular Simulations suggest Vitamins, Retinoids and Steroids as Ligands of the Free Fatty Acid Pocket of the SARS-CoV-2 Spike Protein**. <i>Angewandte Chemie - International Edition</i> , 2021, 60, 7098-7110.	13.8	77
30	Coinfection with influenza A virus enhances SARS-CoV-2 infectivity. <i>Cell Research</i> , 2021, 31, 395-403.	12.0	164
31	COVID-19: Molecular and Cellular Response. <i>Frontiers in Cellular and Infection Microbiology</i> , 2021, 11, 563085.	3.9	31
33	Molecular Simulations suggest Vitamins, Retinoids and Steroids as Ligands of the Free Fatty Acid Pocket of the SARS-CoV-2 Spike Protein**. <i>Angewandte Chemie</i> , 2021, 133, 7174-7186.	2.0	6
34	Differentially conserved amino acid positions may reflect differences in SARS-CoV-2 and SARS-CoV behaviour. <i>Bioinformatics</i> , 2021, 37, 2282-2288.	4.1	9
35	A Comprehensive Review of Viral Characteristics, Transmission, Pathophysiology, Immune Response, and Management of SARS-CoV-2 and COVID-19 as a Basis for Controlling the Pandemic. <i>Frontiers in Immunology</i> , 2021, 12, 631139.	4.8	117
36	Chemokine Regulation During Epidemic Coronavirus Infection. <i>Frontiers in Pharmacology</i> , 2020, 11, 600369.	3.5	15
39	SARS-CoV-2 Triggers an MDA-5-Dependent Interferon Response Which Is Unable To Control Replication in Lung Epithelial Cells. <i>Journal of Virology</i> , 2021, 95, .	3.4	168
40	Systemic diseases and the cornea. <i>Experimental Eye Research</i> , 2021, 204, 108455.	2.6	46

#	ARTICLE	IF	CITATIONS
41	Inhibition of coronavirus infection by a synthetic STING agonist in primary human airway system. <i>Antiviral Research</i> , 2021, 187, 105015.	4.1	33
42	Mesenchymal Stem Cells in the Treatment of New Coronavirus Pandemic: A Novel Promising Therapeutic Approach. <i>Advanced Pharmaceutical Bulletin</i> , 2021, .	1.4	5
43	Ribosome-Profiling Reveals Restricted Post Transcriptional Expression of Antiviral Cytokines and Transcription Factors during SARS-CoV-2 Infection. <i>International Journal of Molecular Sciences</i> , 2021, 22, 3392.	4.1	22
44	A novel cell culture system modeling the SARS-CoV-2 life cycle. <i>PLoS Pathogens</i> , 2021, 17, e1009439.	4.7	102
45	A review of potential suggested drugs for coronavirus disease (COVID-19) treatment. <i>European Journal of Pharmacology</i> , 2021, 895, 173890.	3.5	86
47	Drugs used in the treatment of multiple sclerosis during COVID-19 pandemic: a critical viewpoint. <i>Current Neuropharmacology</i> , 2021, 19, .	2.9	5
48	An Overview of Current Knowledge of Deadly CoVs and Their Interface with Innate Immunity. <i>Viruses</i> , 2021, 13, 560.	3.3	15
49	Transcriptome network analyses in human coronavirus infections suggest a rational use of immunomodulatory drugs for COVID-19 therapy. <i>Genomics</i> , 2021, 113, 564-575.	2.9	12
50	Transnasal endoscopic skull base surgery in the COVID-19 era: Recommendations for increasing the safety of the method. <i>Advances in Medical Sciences</i> , 2021, 66, 221-230.	2.1	10
51	Endogenously Produced SARS-CoV-2 Specific IgG Antibodies May Have a Limited Impact on Clearing Nasal Shedding of Virus during Primary Infection in Humans. <i>Viruses</i> , 2021, 13, 516.	3.3	5
54	Disparate temperature-dependent virus-host dynamics for SARS-CoV-2 and SARS-CoV in the human respiratory epithelium. <i>PLoS Biology</i> , 2021, 19, e3001158.	5.6	79
55	Inflammation, immunity and potential target therapy of SARS-COV-2: A total scale analysis review. <i>Food and Chemical Toxicology</i> , 2021, 150, 112087.	3.6	17
56	Actionable druggable genome-wide Mendelian randomization identifies repurposing opportunities for COVID-19. <i>Nature Medicine</i> , 2021, 27, 668-676.	30.7	120
57	The Polybasic Cleavage Site in SARS-CoV-2 Spike Modulates Viral Sensitivity to Type I Interferon and IFITM2. <i>Journal of Virology</i> , 2021, 95, .	3.4	121
58	Efficacy and safety of pegylated interferon alfa-2b in moderate COVID-19: A phase II, randomized, controlled, open-label study. <i>International Journal of Infectious Diseases</i> , 2021, 105, 516-521.	3.3	54
59	Type I and III IFN-mediated antiviral actions counteracted by SARS-CoV-2 proteins and host inherited factors. <i>Cytokine and Growth Factor Reviews</i> , 2021, 58, 55-65.	7.2	11
60	Novel mutations in NSP-1 and PLPro of SARS-CoV-2 NIB-1 genome mount for effective therapeutics. <i>Journal of Genetic Engineering and Biotechnology</i> , 2021, 19, 52.	3.3	26
61	SARS-CoV-2 vaccines: a triumph of science and collaboration. <i>JCI Insight</i> , 2021, 6, .	5.0	72

#	ARTICLE	IF	CITATIONS
62	Disease-modifying therapies and SARS-CoV-2 vaccination in multiple sclerosis: an expert consensus. <i>Journal of Neurology</i> , 2021, 268, 3961-3968.	3.6	47
64	SARS-CoV-2 induces double-stranded RNA-mediated innate immune responses in respiratory epithelial-derived cells and cardiomyocytes. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2021, 118, .	7.1	159
66	An open-label randomized controlled trial of the effect of lopinavir/ritonavir, lopinavir/ritonavir plus IFN- $\beta$ -1a and hydroxychloroquine in hospitalized patients with COVID-19. <i>Clinical Microbiology and Infection</i> , 2021, 27, 1826-1837.	6.0	77
67	Experimental and natural evidence of SARS-CoV-2-infection-induced activation of type I interferon responses. <i>IScience</i> , 2021, 24, 102477.	4.1	49
68	Type I and III interferon responses in SARS-CoV-2 infection. <i>Experimental and Molecular Medicine</i> , 2021, 53, 750-760.	7.7	187
69	Pharmacological activation of STING blocks SARS-CoV-2 infection. <i>Science Immunology</i> , 2021, 6, .	11.9	123
70	Fat-Soluble Vitamins and the Current Global Pandemic of COVID-19: Evidence-Based Efficacy from Literature Review. <i>Journal of Inflammation Research</i> , 2021, Volume 14, 2091-2110.	3.5	14
71	Promising Immunotherapies against COVID-19. <i>Advanced Therapeutics</i> , 2021, 4, 2100044.	3.2	4
72	SARS-CoV-2 ORF9b antagonizes type I and III interferons by targeting multiple components of the RIG-I/MDA5-MAVS, TLR3-TRIF, and cGAS-STING signaling pathways. <i>Journal of Medical Virology</i> , 2021, 93, 5376-5389.	9.3	153
74	Type-I interferon signatures in SARS-CoV-2 infected Huh7 cells. <i>Cell Death Discovery</i> , 2021, 7, 114.	4.7	23
75	Nasopharyngeal Type-I Interferon for Immediately Available Prophylaxis Against Emerging Respiratory Viral Infections. <i>Frontiers in Immunology</i> , 2021, 12, 660298.	4.8	8
77	A brief molecular insight of COVID-19: epidemiology, clinical manifestation, molecular mechanism, cellular tropism and immuno-pathogenesis. <i>Molecular and Cellular Biochemistry</i> , 2021, 476, 3987-4002.	3.1	6
78	Variants in ACE2; potential influences on virus infection and COVID-19 severity. <i>Infection, Genetics and Evolution</i> , 2021, 90, 104773.	2.3	72
81	SARS-CoV-2 Portrayed against HIV: Contrary Viral Strategies in Similar Disguise. <i>Microorganisms</i> , 2021, 9, 1389.	3.6	4
82	Inhibiting SARS-CoV-2-ribosome interactions. <i>Communications Biology</i> , 2021, 4, 715.	4.4	29
83	Critical Determinants of Cytokine Storm and Type I Interferon Response in COVID-19 Pathogenesis. <i>Clinical Microbiology Reviews</i> , 2021, 34, .	13.6	141
85	A Hepatitis B Virus-Derived Peptide Can Inhibit Infection of Human Lung Cells with SARS-CoV-2 in a Type-1 Interferon-Dependent Manner. <i>Viruses</i> , 2021, 13, 1227.	3.3	3
86	Functional landscape of SARS-CoV-2 cellular restriction. <i>Molecular Cell</i> , 2021, 81, 2656-2668.e8.	9.7	137

#	ARTICLE	IF	CITATIONS
87	Conflicting and ambiguous names of overlapping ORFs in the SARS-CoV-2 genome: A homology-based resolution. <i>Virology</i> , 2021, 558, 145-151.	2.4	40
88	Dynamic innate immune response determines susceptibility to SARS-CoV-2 infection and early replication kinetics. <i>Journal of Experimental Medicine</i> , 2021, 218, .	8.5	139
89	SARS-CoV-2 Spike Protein Suppresses ACE2 and Type I Interferon Expression in Primary Cells From Macaque Lung Bronchoalveolar Lavage. <i>Frontiers in Immunology</i> , 2021, 12, 658428.	4.8	30
90	Human Kidney Spheroids and Monolayers Provide Insights into SARS-CoV-2 Renal Interactions. <i>Journal of the American Society of Nephrology: JASN</i> , 2021, 32, 2242-2254.	6.1	24
91	SARS-CoV-2 Antiviral Therapy. <i>Clinical Microbiology Reviews</i> , 2021, 34, e0010921.	13.6	64
92	Impact of COVID-19 on patients with atopic dermatitis. <i>Clinics in Dermatology</i> , 2021, 39, 1083-1087.	1.6	7
93	IFN- $\gamma$ reduces NRP-1 expression on human cord blood monocytes and inhibits VEGF-induced chemotaxis. <i>Cytokine</i> , 2021, 143, 155519.	3.2	0
94	Long noncoding RNAs in respiratory viruses: A review. <i>Reviews in Medical Virology</i> , 2022, 32, e2275.	8.3	13
95	Innate immune and inflammatory responses to SARS-CoV-2: Implications for COVID-19. <i>Cell Host and Microbe</i> , 2021, 29, 1052-1062.	11.0	185
96	SARS-CoV-2 infection in the Syrian hamster model causes inflammation as well as type I interferon dysregulation in both respiratory and non-respiratory tissues including the heart and kidney. <i>PLoS Pathogens</i> , 2021, 17, e1009705.	4.7	60
98	Pharmacotherapy in Coronavirus Disease 2019 and Risk of Secondary Infections: A Single-Center Case Series and Narrative Review. , 2021, 3, e0492.		6
99	COVID-19 virtual patient cohort suggests immune mechanisms driving disease outcomes. <i>PLoS Pathogens</i> , 2021, 17, e1009753.	4.7	61
101	The Pathogenic Features of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2): Possible Mechanisms for Immune Evasion?. <i>Frontiers in Immunology</i> , 2021, 12, 693579.	4.8	2
102	Targeting liquid-liquid phase separation of SARS-CoV-2 nucleocapsid protein promotes innate antiviral immunity by elevating MAVS activity. <i>Nature Cell Biology</i> , 2021, 23, 718-732.	10.3	156
103	Systematic analysis of SARS-CoV-2 infection of an ACE2-negative human airway cell. <i>Cell Reports</i> , 2021, 36, 109364.	6.4	109
104	Lack of active SARS-CoV-2 virus in a subset of PCR-positive COVID-19 congregate care patients. <i>Journal of Clinical Virology</i> , 2021, 141, 104879.	3.1	3
105	Endothelial Dysfunction, Inflammation, and Oxidative Stress in COVID-19—Mechanisms and Therapeutic Targets. <i>Oxidative Medicine and Cellular Longevity</i> , 2021, 2021, 1-15.	4.0	66
106	Intranasal type I interferon treatment is beneficial only when administered before clinical signs onset in the SARS-CoV-2 hamster model. <i>PLoS Pathogens</i> , 2021, 17, e1009427.	4.7	38

#	ARTICLE	IF	CITATIONS
107	SARS-CoV-2 pseudovirus infectivity and expression of viral entry-related factors ACE2, TMPRSS2, Kim1, and NRP1 in human cells from the respiratory, urinary, digestive, reproductive, and immune systems. <i>Journal of Medical Virology</i> , 2021, 93, 6671-6685.	5.0	26
109	Type I Interferons in COVID-19 Pathogenesis. <i>Biology</i> , 2021, 10, 829.	2.8	32
110	Interferon and Toll-Like Receptor 7 Response in COVID-19: Implications of Topical Imiquimod for Prophylaxis and Treatment. <i>Dermatology</i> , 2021, 237, 847-856.	2.1	5
111	Transcriptomic Signatures of Airway Epithelium Infected With SARS-CoV-2: A Balance Between Anti-infection and Virus Load. <i>Frontiers in Cell and Developmental Biology</i> , 2021, 9, 735307.	3.7	3
112	SARS-CoV-2 suppresses IFN $\gamma$ production mediated by NSP1, 5, 6, 15, ORF6 and ORF7b but does not suppress the effects of added interferon. <i>PLoS Pathogens</i> , 2021, 17, e1009800.	4.7	74
113	A robust SARS-CoV-2 replication model in primary human epithelial cells at the air liquid interface to assess antiviral agents. <i>Antiviral Research</i> , 2021, 192, 105122.	4.1	47
114	Intracellular Life Cycle Kinetics of SARS-CoV-2 Predicted Using Mathematical Modelling. <i>Viruses</i> , 2021, 13, 1735.	3.3	15
115	Induction of interferon response by high viral loads at early stage infection may protect against severe outcomes in COVID-19 patients. <i>Scientific Reports</i> , 2021, 11, 15715.	3.3	15
116	Pre-activated antiviral innate immunity in the upper airways controls early SARS-CoV-2 infection in children. <i>Nature Biotechnology</i> , 2022, 40, 319-324.	17.5	229
118	The role of type I interferon in the treatment of COVID-19. <i>Journal of Medical Virology</i> , 2022, 94, 63-81.	5.0	52
119	Multiple Sclerosis and SARS-CoV-2: Has the Interplay Started?. <i>Frontiers in Immunology</i> , 2021, 12, 755333.	4.8	33
120	Immunisation of ferrets and mice with recombinant SARS-CoV-2 spike protein formulated with Advax-SM adjuvant protects against COVID-19 infection. <i>Vaccine</i> , 2021, 39, 5940-5953.	3.8	44
121	Immunobiotic Lactobacilli Improve Resistance of Respiratory Epithelial Cells to SARS-CoV-2 Infection. <i>Pathogens</i> , 2021, 10, 1197.	2.8	11
122	Interferon $\gamma$ , an enhancer of the innate immune response against SARS-CoV-2 infection. <i>Microbial Pathogenesis</i> , 2021, 158, 105105.	2.9	6
123	Mechanisms of Antiviral Immune Evasion of SARS-CoV-2. <i>Journal of Molecular Biology</i> , 2022, 434, 167265.	4.2	72
124	Inhibition of IRGM establishes a robust antiviral immune state to restrict pathogenic viruses. <i>EMBO Reports</i> , 2021, 22, e52948.	4.5	17
125	The NF- $\kappa$ B Transcriptional Footprint Is Essential for SARS-CoV-2 Replication. <i>Journal of Virology</i> , 2021, 95, e0125721.	3.4	69
126	A Role of Variance in Interferon Genes to Disease Severity in COVID-19 Patients. <i>Frontiers in Genetics</i> , 2021, 12, 709388.	2.3	9

#	ARTICLE	IF	CITATIONS
127	Severe Acute Respiratory Syndrome Coronavirus 2: The Role of the Main Components of the Innate Immune System. <i>Inflammation</i> , 2021, 44, 2151-2169.	3.8	11
128	Beyond Vaccines: Clinical Status of Prospective COVID-19 Therapeutics. <i>Frontiers in Immunology</i> , 2021, 12, 752227.	4.8	25
129	Efficacy and safety of pegylated interferon- $\beta$ 2b in moderate COVID-19: a phase 3, randomized, comparator-controlled, open-label study. <i>International Journal of Infectious Diseases</i> , 2021, 111, 281-287.	3.3	21
130	An overview of human proteins and genes involved in SARS-CoV-2 infection. <i>Gene</i> , 2022, 808, 145963.	2.2	22
131	Antiviral Activity of Azithromycin (A Synthetic Macrolide) for Next Step of COVID-19. <i>Asian Journal of Chemistry</i> , 2021, 33, 1594-1602.	0.3	0
132	SARS-CoV-2 Infection of Airway Epithelial Cells. <i>Immune Network</i> , 2021, 21, e3.	3.6	43
133	Architected Therapeutic and Diagnostic Nanoplatfoms for Combating SARS-CoV-2: Role of Inorganic, Organic, and Radioactive Materials. <i>ACS Biomaterials Science and Engineering</i> , 2021, 7, 31-54.	5.2	19
134	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) membrane (M) protein inhibits type I and III interferon production by targeting RIG-I/MDA-5 signaling. <i>Signal Transduction and Targeted Therapy</i> , 2020, 5, 299.	17.1	232
138	A Guide to COVID-19: a global pandemic caused by the novel coronavirus SARS-CoV-2. <i>FEBS Journal</i> , 2020, 287, 3633-3650.	4.7	192
139	Endothelium Infection and Dysregulation by SARS-CoV-2: Evidence and Caveats in COVID-19. <i>Viruses</i> , 2021, 13, 29.	3.3	118
140	Towards a more effective strategy for COVID-19 prevention (Review). <i>Experimental and Therapeutic Medicine</i> , 2020, 21, 1-1.	1.8	4
141	Dynamically evolving novel overlapping gene as a factor in the SARS-CoV-2 pandemic. <i>ELife</i> , 2020, 9, .	6.0	74
142	Immunology of SARS-CoV-2 infections and vaccines. <i>Advances in Immunology</i> , 2021, 151, 49-97.	2.2	12
143	A review: Antibody-dependent enhancement in COVID-19: The not so friendly side of antibodies. <i>International Journal of Immunopathology and Pharmacology</i> , 2021, 35, 205873842110501.	2.1	26
144	Multicellular spatial model of RNA virus replication and interferon responses reveals factors controlling plaque growth dynamics. <i>PLoS Computational Biology</i> , 2021, 17, e1008874.	3.2	8
145	Differential roles of interferons in innate responses to mucosal viral infections. <i>Trends in Immunology</i> , 2021, 42, 1009-1023.	6.8	39
146	Risk and Impact of Severe Acute Respiratory Syndrome Coronavirus 2 Infection on Corneal Transplantation: A Case-Control Study. <i>Cornea</i> , 2022, 41, 224-231.	1.7	1
147	Clash of the titans: interferons and SARS-CoV-2. <i>Trends in Immunology</i> , 2021, 42, 1069-1072.	6.8	10



#	ARTICLE	IF	CITATIONS
148	Efficacy of interferon beta-1a plus remdesivir compared with remdesivir alone in hospitalised adults with COVID-19: a double-blind, randomised, placebo-controlled, phase 3 trial. <i>Lancet Respiratory Medicine</i> , 2021, 9, 1365-1376.	10.7	119
149	Cancer and Covid-19: Collectively catastrophic. <i>Cytokine and Growth Factor Reviews</i> , 2022, 63, 78-89.	7.2	10
150	Efficacy of Interferon- $\beta$ in Moderate-to-Severe Hospitalised Cases of COVID-19: A Systematic Review and Meta-analysis. <i>Clinical Drug Investigation</i> , 2021, 41, 1037-1046.	2.2	7
151	Hamster organotypic modeling of SARS-CoV-2 lung and brainstem infection. <i>Nature Communications</i> , 2021, 12, 5809.	12.8	37
152	Comparing the outcomes of treatment with INF- $\beta$ 1-a (interferon beta-1a) and IFN- $\beta$ 1-b (interferon beta-1b) among COVID-19 inpatients. <i>International Immunopharmacology</i> , 2021, 101, 108241.	3.8	1
154	Untapping host-targeting cross-protective efficacy of anticoagulants against SARS-CoV-2. , 2022, 233, 108027.		2
156	Immunopathology and Immunopathogenesis of COVID-19, what we know and what we should learn. <i>Gene Reports</i> , 2021, 25, 101417.	0.8	15
157	Impaired innate antiviral defenses in COVID-19: Causes, consequences and therapeutic opportunities. <i>Seminars in Immunology</i> , 2021, 55, 101522.	5.6	12
159	Bovine Interferon Lambda Is a Potent Antiviral Against SARS-CoV-2 Infection in vitro. <i>Frontiers in Veterinary Science</i> , 2020, 7, 603622.	2.2	5
160	Generation of a Novel SARS-CoV-2 Sub-genomic RNA Due to the R203K/G204R Variant in Nucleocapsid: Homologous Recombination has Potential to Change SARS-CoV-2 at Both Protein and RNA Level. <i>Pathogens and Immunity</i> , 2021, 6, 27-49.	3.1	10
161	Devil's tools: SARS-CoV-2 antagonists against innate immunity. <i>Current Research in Virological Science</i> , 2021, 2, 100013.	3.5	19
162	Host cell-intrinsic innate immune recognition of SARS-CoV-2. <i>Current Opinion in Virology</i> , 2022, 52, 30-38.	5.4	32
163	Generation of a Novel SARS-CoV-2 Sub-genomic RNA Due to the R203K/G204R Variant in Nucleocapsid: Homologous Recombination has Potential to Change SARS-CoV-2 at Both Protein and RNA Level. <i>Pathogens and Immunity</i> , 2021, 6, 27-49.	3.1	46
164	TLRs in COVID-19: How they drive immunopathology and the rationale for modulation. <i>Innate Immunity</i> , 2021, 27, 503-513.	2.4	32
165	Immune dysregulation and immunopathology induced by SARS-CoV-2 and related coronaviruses "are we our own worst enemy?". <i>Nature Reviews Immunology</i> , 2022, 22, 47-56.	22.7	118
167	ORAI1 Limits SARS-CoV-2 Infection by Regulating Tonic Type I IFN Signaling. <i>Journal of Immunology</i> , 2022, 208, 74-84.	0.8	12
168	TMPRSS2 promotes SARS-CoV-2 evasion from NCOA7-mediated restriction. <i>PLoS Pathogens</i> , 2021, 17, e1009820.	4.7	13
169	Why Females Do Better: The X Chromosomal TLR7 Gene-Dose Effect in COVID-19. <i>Frontiers in Immunology</i> , 2021, 12, 756262.	4.8	35

#	ARTICLE	IF	CITATIONS
170	A Narrative Review of Existing Options for COVID-19-Specific Treatments. <i>Advances in Virology</i> , 2021, 2021, 1-13.	1.1	0
171	Deep Time Course Proteomics of SARS-CoV- and SARS-CoV-2-Infected Human Lung Epithelial Cells (Calu-3) Reveals Strong Induction of Interferon-Stimulated Gene Expression by SARS-CoV-2 in Contrast to SARS-CoV. <i>Journal of Proteome Research</i> , 2022, 21, 459-469.	3.7	16
172	All hands on deck: SARS-CoV-2 proteins that block early anti-viral interferon responses. <i>Current Research in Virological Science</i> , 2021, 2, 100015.	3.5	26
173	Human genetic and immunological determinants of critical COVID-19 pneumonia. <i>Nature</i> , 2022, 603, 587-598.	27.8	216
175	Immune-Guided Therapy of COVID-19. <i>Cancer Immunology Research</i> , 2022, 10, 384-402.	3.4	20
176	Elimination of Aicardiâ€“GoutiÃ“res syndrome protein SAMHD1 activates cellular innate immunity and suppresses SARS-CoV-2 replication. <i>Journal of Biological Chemistry</i> , 2022, 298, 101635.	3.4	9
177	The Inhibition of RNA Viruses by <i>Amaryllidaceae</i> Alkaloids: Opportunities for the Development of Broadâ€“spectrum Antiâ€“Coronavirus Drugs. <i>Chemistry - an Asian Journal</i> , 2022, 17, e202101215.	3.3	6
178	Type I interferons and SARS-CoV-2: from cells to organisms. <i>Current Opinion in Immunology</i> , 2022, 74, 172-182.	5.5	49
180	Deciphering Respiratory-Virus-Associated Interferon Signaling in COPD Airway Epithelium. <i>Medicina (Lithuania)</i> , 2022, 58, 121.	2.0	6
181	Alpha-Soluble NSF Attachment Protein Prevents the Cleavage of the SARS-CoV-2 Spike Protein by Functioning as an Interferon-Upregulated Furin Inhibitor. <i>MBio</i> , 2022, 13, e0244321.	4.1	8
182	Whatâ€™s happening where when SARS-CoV-2 infects: are TLR7 and MAFB sufficient to explain patient vulnerability?. <i>Immunity and Ageing</i> , 2022, 19, 6.	4.2	7
183	Interferon Control of Human Coronavirus Infection and Viral Evasion: Mechanistic Insights and Implications for Antiviral Drug and Vaccine Development. <i>Journal of Molecular Biology</i> , 2022, 434, 167438.	4.2	7
184	Coordinated regulation of interferon and inflammasome signaling pathways by SARS-CoV-2 proteins. <i>Journal of Microbiology</i> , 2022, 60, 300-307.	2.8	6
185	Differential interferon-Î± subtype induced immune signatures are associated with suppression of SARS-CoV-2 infection. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2022, 119, .	7.1	33
186	A Detailed Overview of Immune Escape, Antibody Escape, Partial Vaccine Escape of SARS-CoV-2 and Their Emerging Variants With Escape Mutations. <i>Frontiers in Immunology</i> , 2022, 13, 801522.	4.8	73
187	Myeloid cell interferon responses correlate with clearance of SARS-CoV-2. <i>Nature Communications</i> , 2022, 13, 679.	12.8	30
188	RIG-I-induced innate antiviral immunity protects mice from lethal SARS-CoV-2 infection. <i>Molecular Therapy - Nucleic Acids</i> , 2022, 27, 1225-1234.	5.1	14
189	The severe acute respiratory syndrome coronavirus 2 non-structural proteins 1 and 15 proteins mediate antiviral immune evasion. <i>Current Research in Virological Science</i> , 2022, 3, 100021.	3.5	6

#	ARTICLE	IF	CITATIONS
190	Therapeutic Options for Coronavirus Disease 2019 (COVID-19): Where Are We Now?. <i>Current Infectious Disease Reports</i> , 2021, 23, 28.	3.0	5
191	Waves and variants of SARS-CoV-2: understanding the causes and effect of the COVID-19 catastrophe. <i>Infection</i> , 2022, 50, 309-325.	4.7	112
192	Delayed induction of type I and III interferons mediates nasal epithelial cell permissiveness to SARS-CoV-2. <i>Nature Communications</i> , 2021, 12, 7092.	12.8	65
193	The role of respiratory microbiota in the protection against viral diseases: respiratory commensal bacteria as next-generation probiotics for COVID-19. <i>Bioscience of Microbiota, Food and Health</i> , 2022, , .	1.8	8
194	&lt;i>in vitro&/i> antiviral activity of VIFERONÂ® rectal suppositories against SARS-CoV-2. <i>Russian Journal of Infection and Immunity</i> , 2022, 12, 142-148.	0.7	1
195	The RNA helicase DHX16 recognizes specific viral RNA to trigger RIG-I-dependent innate antiviral immunity. <i>Cell Reports</i> , 2022, 38, 110434.	6.4	16
196	Adopting Natural Host Immune Response Against Zoonosis. <i>Journal of Education, Management and Development Studies</i> , 2022, 2, 52-66.	0.3	0
197	Increased Sensitivity of SARS-CoV-2 to Type III Interferon in Human Intestinal Epithelial Cells. <i>Journal of Virology</i> , 2022, 96, e0170521.	3.4	17
198	COVID-19: impact on Public Health and hypothesis-driven investigations on genetic susceptibility and severity. <i>Immunogenetics</i> , 2022, 74, 381-407.	2.4	5
199	SARS-CoV-2 pathogenesis. <i>Nature Reviews Microbiology</i> , 2022, 20, 270-284.	28.6	404
201	Interferon antagonists encoded by SARS-CoV-2 at a glance. <i>Medical Microbiology and Immunology</i> , 2023, 212, 125-131.	4.8	20
202	A multi-tissue study of immune gene expression profiling highlights the key role of the nasal epithelium in COVID-19 severity. <i>Environmental Research</i> , 2022, 210, 112890.	7.5	23
203	Post-COVID-19 arthritis: is it hyperinflammation or autoimmunity?. <i>European Cytokine Network</i> , 2021, 32, 83-88.	2.0	22
204	Local and systemic responses to SARS-CoV-2 infection in children and adults. <i>Nature</i> , 2022, 602, 321-327.	27.8	179
205	Clinical Experience with Ropoginterferon Alfa-2b in the Off-Label Use for the Treatment of COVID-19 Patients in Taiwan. <i>Advances in Therapy</i> , 2022, 39, 910-922.	2.9	6
206	Can the immune system be targeted to treat COVID-19?. , 2021, , 69-85.		1
207	Identification of transcriptional regulatory network associated with response of host epithelial cells to SARS-CoV-2. <i>Scientific Reports</i> , 2021, 11, 23928.	3.3	2
208	Inducible CRISPR activation screen for interferon-stimulated genes identifies OAS1 as a SARS-CoV-2 restriction factor. <i>PLoS Pathogens</i> , 2022, 18, e1010464.	4.7	24

#	ARTICLE	IF	CITATIONS
212	Immune Signature of COVID-19: In-Depth Reasons and Consequences of the Cytokine Storm. <i>International Journal of Molecular Sciences</i> , 2022, 23, 4545.	4.1	11
213	Identification of DAXX as a restriction factor of SARS-CoV-2 through a CRISPR/Cas9 screen. <i>Nature Communications</i> , 2022, 13, 2442.	12.8	25
215	The Evolutionary Dance between Innate Host Antiviral Pathways and SARS-CoV-2. <i>Pathogens</i> , 2022, 11, 538.	2.8	4
216	Enrichment analysis on regulatory subspaces: A novel direction for the superior description of cellular responses to SARS-CoV-2. <i>Computers in Biology and Medicine</i> , 2022, 146, 105443.	7.0	0
217	Omicron variant of SARS-CoV-2 exhibits an increased resilience to the antiviral type I interferon response. , 2022, 1, .		16
218	Type-I interferons in the immunopathogenesis and treatment of Coronavirus disease 2019. <i>European Journal of Pharmacology</i> , 2022, 927, 175051.	3.5	9
219	Dopamine Reduces SARS-CoV-2 Replication In Vitro through Downregulation of D2 Receptors and Upregulation of Type-I Interferons. <i>Cells</i> , 2022, 11, 1691.	4.1	9
220	The Translational Landscape of SARS-CoV-2-infected Cells Reveals Suppression of Innate Immune Genes. <i>MBio</i> , 2022, 13, .	4.1	21
221	The Role of Antibodies in the Treatment of SARS-CoV-2 Virus Infection, and Evaluating Their Contribution to Antibody-Dependent Enhancement of Infection. <i>International Journal of Molecular Sciences</i> , 2022, 23, 6078.	4.1	4
222	Increased LAMP1 Expression Enhances SARS-CoV-1 and SARS-CoV-2 Production in Vero-Derived Transgenic Cell Lines. <i>Molecular Biology</i> , 2022, 56, 463-468.	1.3	2
223	Absence of negativization of nasal swab test and frailty as risk factors for mortality in elderly COVID-19 patients admitted in long-term care facilities. <i>European Geriatric Medicine</i> , 2022, 13, 933-939.	2.8	3
224	Implicating effector genes at COVID-19 GWAS loci using promoter-focused Capture-C in disease-relevant immune cell types. <i>Genome Biology</i> , 2022, 23, .	8.8	12
225	The impact of SARS-CoV-2 treatment on the cardiovascular system: an updated review. <i>Inflammopharmacology</i> , 2022, 30, 1143-1151.	3.9	4
226	Identifying enhancers of innate immune signaling as broad-spectrum antivirals active against emerging viruses. <i>Cell Chemical Biology</i> , 2022, 29, 1113-1125.e6.	5.2	10
227	Cytokines and microRNAs in SARS-CoV-2: What do we know?. <i>Molecular Therapy - Nucleic Acids</i> , 2022, 29, 219-242.	5.1	18
228	Production of a functionally active recombinant SARS-CoV-2 (COVID-19) 3C-like protease and a soluble inactive 3C-like protease-RBD chimeric in a prokaryotic expression system. <i>Epidemiology and Infection</i> , 2022, 150, .	2.1	0
229	HYGIEIA: HYpothesizing the Genesis of Infectious Diseases and Epidemics through an Integrated Systems Biology Approach. <i>Viruses</i> , 2022, 14, 1373.	3.3	2
230	Characterization of SARS-CoV-2 Evasion: Interferon Pathway and Therapeutic Options. <i>Viruses</i> , 2022, 14, 1247.	3.3	24

#	ARTICLE	IF	CITATIONS
231	Attenuation of SARS-CoV-2 replication and associated inflammation by concomitant targeting of viral and host cap 2' O <sup>6</sup> -methyltransferases. <i>EMBO Journal</i> , 2022, 41, .	7.8	18
232	A Review on Immunological Responses to SARS-CoV-2 and Various COVID-19 Vaccine Regimens. <i>Pharmaceutical Research</i> , 2022, 39, 2119-2134.	3.5	10
233	Exploring the Immunomodulatory Aspect of Mesenchymal Stem Cells for Treatment of Severe Coronavirus Disease 19. <i>Cells</i> , 2022, 11, 2175.	4.1	7
234	Innate immunity to SARS-CoV-2 infection: A review. <i>Epidemiology and Infection</i> , 0, , 1-49.	2.1	9
235	A comprehensive evaluation of the immune system response and type-I Interferon signaling pathway in hospitalized COVID-19 patients. <i>Cell Communication and Signaling</i> , 2022, 20, .	6.5	19
236	A Path-Based Analysis of Infected Cell Line and COVID-19 Patient Transcriptome Reveals Novel Potential Targets and Drugs Against SARS-CoV-2. <i>Frontiers in Immunology</i> , 0, 13, .	4.8	6
237	COPD, but Not Asthma, Is Associated with Worse Outcomes in COVID-19: Real-Life Data from Four Main Centers in Northwest Italy. <i>Journal of Personalized Medicine</i> , 2022, 12, 1184.	2.5	1
238	SARS-CoV-2 impairs interferon production via NSP2-induced repression of mRNA translation. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2022, 119, .	7.1	28
239	Comprehensive Subcellular Localization of Swine Acute Diarrhea Syndrome Coronavirus Proteins. <i>Journal of Virology</i> , 2022, 96, .	3.4	1
240	Self-assembling short immunostimulatory duplex RNAs with broad-spectrum antiviral activity. <i>Molecular Therapy - Nucleic Acids</i> , 2022, 29, 923-940.	5.1	7
241	Importancia de los Interferones en la respuesta inmune antiviral contra SARS-CoV-2. <i>Revista De La Universidad Industrial De Santander Salud</i> , 2022, 54, .	0.2	0
242	An Orally Administered Nonpathogenic Attenuated Vaccine Virus Can Be Used to Control SARS-CoV-2 Infection: A Complementary Plan B to COVID-19 Vaccination. <i>Cureus</i> , 2022, , .	0.5	3
243	SARS-CoV-2 Variant Delta Potently Suppresses Innate Immune Response and Evades Interferon-Activated Antiviral Responses in Human Colon Epithelial Cells. <i>Microbiology Spectrum</i> , 2022, 10, .	3.0	9
244	Pharmacologic therapies of ARDS: From natural herb to nanomedicine. <i>Frontiers in Pharmacology</i> , 0, 13, .	3.5	4
245	Choosing a cellular model to study SARS-CoV-2. <i>Frontiers in Cellular and Infection Microbiology</i> , 0, 12, .	3.9	22
246	Early suppression of antiviral host response and protocadherins by SARS-CoV-2 Spike protein in THP-1-derived macrophage-like cells. <i>Frontiers in Immunology</i> , 0, 13, .	4.8	0
248	GPR183 antagonism reduces macrophage infiltration in influenza and SARS-CoV-2 infection. <i>European Respiratory Journal</i> , 2023, 61, 2201306.	6.7	15
249	Nonspecific Effects of Infant Vaccines Make Children More Resistant to SARS-CoV-2 Infection. <i>Children</i> , 2022, 9, 1858.	1.5	2

#	ARTICLE	IF	CITATIONS
250	Transcription factor Nrf2 as a potential therapeutic target for COVID-19. <i>Cell Stress and Chaperones</i> , 2023, 28, 11-20.	2.9	4
251	Molecular Function of cGAS-STING in SARS-CoV-2: A Novel Approach to COVID-19 Treatment. <i>BioMed Research International</i> , 2022, 2022, 1-10.	1.9	3
252	Nanomaterials to combat SARS-CoV-2: Strategies to prevent, diagnose and treat COVID-19. <i>Frontiers in Bioengineering and Biotechnology</i> , 0, 10, .	4.1	3
253	Potential role of AIM2 inflammasome in SARS-CoV-2 infection. <i>Scandinavian Journal of Immunology</i> , 2023, 97, .	2.7	2
254	Type I interferon signaling in SARS-CoV-2 associated neurocognitive disorder (SAND): Mapping host-virus interactions to an etiopathogenesis. <i>Frontiers in Neurology</i> , 0, 13, .	2.4	4
255	Cellular APOBEC3A deaminase drives mutations in the SARS-CoV-2 genome. <i>Nucleic Acids Research</i> , 2023, 51, 783-795.	14.5	21
256	Innate immune evasion strategies of SARS-CoV-2. <i>Nature Reviews Microbiology</i> , 0, , .	28.6	31
257	The Safety and Efficacy of the Protease Inhibitors Lopinavir/Ritonavir as Monotherapy or Combined with Interferon in COVID-19 Patients. <i>Processes</i> , 2023, 11, 398.	2.8	0
258	SARS-CoV-2 Establishes a Productive Infection in Hepatoma and Glioblastoma Multiforme Cell Lines. <i>Cancers</i> , 2023, 15, 632.	3.7	3
259	Efficacy of interferon alpha for the treatment of hospitalized patients with COVID-19: A meta-analysis. <i>Frontiers in Immunology</i> , 0, 14, .	4.8	10
260	The main protease of SARS-CoV-2 downregulates innate immunity via a translational repression. <i>Signal Transduction and Targeted Therapy</i> , 2023, 8, .	17.1	1
261	SARS-CoV-2 NSP7 inhibits type I and III IFN production by targeting the RIG-1/MDA5, TRIF, and STING signaling pathways. <i>Journal of Medical Virology</i> , 2023, 95, .	5.0	14
262	Immunometabolic Signature during Respiratory Viral Infection: A Potential Target for Host-Directed Therapies. <i>Viruses</i> , 2023, 15, 525.	3.3	2
264	Mechanistic insight into the protective and pathogenic immune-responses against SARS-CoV-2. <i>Molecular Immunology</i> , 2023, 156, 111-126.	2.2	5
265	Cardiovascular-related proteomic changes in ECFCs exposed to the serum of COVID-19 patients. <i>International Journal of Biological Sciences</i> , 2023, 19, 1664-1680.	6.4	0
266	SARS-CoV-2 Inhibits NRF2-Mediated Antioxidant Responses in Airway Epithelial Cells and in the Lung of a Murine Model of Infection. <i>Microbiology Spectrum</i> , 2023, 11, .	3.0	11
267	Assessment of the potential value of combining western medicine therapies with traditional chinese medicine in the treatment of COVID-19: Mechanistic perspectives. <i>Technology and Health Care</i> , 2023, , 1-16.	1.2	0
268	Analysis of the Differential Expression and Antiviral Activity of Porcine Interferon- $\beta$ In Vitro. <i>International Journal of Peptide Research and Therapeutics</i> , 2023, 29, .	1.9	1

#	ARTICLE	IF	CITATIONS
269	Plasmacytoid dendritic cells stimulated with <i>Lactococcus lactis</i> strain Plasma produce soluble factors to suppress SARS-CoV-2 replication. <i>Biochemical and Biophysical Research Communications</i> , 2023, 662, 26-30.	2.1	1
271	Interfering with Interferons: A Critical Mechanism for Critical COVID-19 Pneumonia. <i>Annual Review of Immunology</i> , 2023, 41, 561-585.	21.8	15
272	Potential of Interferon Lambda as an Inhibitor of SARS-CoV-2. <i>Molecular Biology</i> , 2023, 57, 291-298.	1.3	1
273	Interferon regulatory factor 3 mediates effective antiviral responses to human coronavirus 229E and OC43 infection. <i>Frontiers in Immunology</i> , 0, 14, .	4.8	5
274	Antiviral Therapy of COVID-19. <i>International Journal of Molecular Sciences</i> , 2023, 24, 8867.	4.1	7
276	The value of Interferon $\hat{I}^2$ in multiple sclerosis and novel opportunities for its anti-viral activity: a narrative literature review. <i>Frontiers in Immunology</i> , 0, 14, .	4.8	5
277	The RNA Interference Effector Protein Argonaute 2 Functions as a Restriction Factor Against SARS-CoV-2. <i>Journal of Molecular Biology</i> , 2023, 435, 168170.	4.2	4
278	Immunomodulatory Role of Interferons in Viral and Bacterial Infections. <i>International Journal of Molecular Sciences</i> , 2023, 24, 10115.	4.1	9
279	Reconsideration of interferon treatment for viral diseases: Lessons from SARS, MERS, and COVID-19. <i>International Immunopharmacology</i> , 2023, 121, 110485.	3.8	0
280	Interferon at the crossroads of SARS-CoV-2 infection and COVID-19 disease. <i>Journal of Biological Chemistry</i> , 2023, 299, 104960.	3.4	5
281	SARS-CoV-2 ORF6 protein does not antagonize interferon signaling in respiratory epithelial Calu-3 cells during infection. <i>MBio</i> , 0, , .	4.1	2
282	Contribution to pathogenesis of accessory proteins of deadly human coronaviruses. <i>Frontiers in Cellular and Infection Microbiology</i> , 0, 13, .	3.9	4
283	Biological mechanisms underpinning the development of long COVID. <i>IScience</i> , 2023, 26, 106935.	4.1	5
285	A single inactivating amino acid change in the SARS-CoV-2 NSP3 Mac1 domain attenuates viral replication in vivo. <i>PLoS Pathogens</i> , 2023, 19, e1011614.	4.7	3
286	Co-infection of mice with SARS-CoV-2 and <i>Mycobacterium tuberculosis</i> limits early viral replication but does not affect mycobacterial loads. <i>Frontiers in Immunology</i> , 0, 14, .	4.8	4
287	Clinical and immunological efficacy of intranasal interferon in the post-vaccination period in patients vaccinated against SARS-CoV-2 coronavirus. <i>Russian Journal of Immunology: RJl: Official Journal of Russian Society of Immunology</i> , 2023, 26, 705-712.	0.4	0
288	Type I/type III IFN and related factors regulate JEV infection and BBB endothelial integrity. <i>Journal of Neuroinflammation</i> , 2023, 20, .	7.2	0
289	Plant and animal positive-sense single-stranded RNA viruses encode small proteins important for viral infection in their negative-sense strand. <i>Molecular Plant</i> , 2023, 16, 1794-1810.	8.3	6

#	ARTICLE	IF	CITATIONS
290	SARS-CoV-2 replicates in the human testis with slow kinetics and has no major deleterious effects <i>in vivo</i> . <i>Journal of Virology</i> , 0, , .	3.4	0
291	Generation of quality-controlled SARS-CoV-2 variant stocks. <i>Nature Protocols</i> , 0, , .	12.0	0
292	SARS-CoV-2 and innate immunity: the good, the bad, and the "goldilocks", 2024, 21, 171-183.		4
293	Participation of Single-Nucleotide Variants in IFNAR1 and IFNAR2 in the Immune Response against SARS-CoV-2 Infection: A Systematic Review. <i>Pathogens</i> , 2023, 12, 1320.	2.8	1
295	Type I interferon signaling induces a delayed antiproliferative response in respiratory epithelial cells during SARS-CoV-2 infection. <i>Journal of Virology</i> , 0, , .	3.4	0
296	Bacterial-induced or passively administered interferon gamma conditions the lung for early control of SARS-CoV-2. <i>Nature Communications</i> , 2023, 14, .	12.8	3
301	Interferon- $\beta$ as a Potential Inhibitor of SARS-CoV-2 ORF6 Accessory Protein. <i>International Journal of Molecular Sciences</i> , 2024, 25, 2155.	4.1	0
302	The Wnt/ $\beta$ -catenin pathway is important for replication of SARS-CoV-2 and other pathogenic RNA viruses. , 2024, 2, .		0
303	The Effects of SARS-CoV-2 on the Angiotensin/Tie Axis and the Vascular Endothelium. <i>Encyclopedia</i> , 2024, 4, 544-557.	4.5	0